IM Cannabis (IMCC)
(Delayed Data from NSDQ)
$2.26 USD
+0.01 (0.65%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $2.26 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.26 USD
+0.01 (0.65%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $2.26 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth C Momentum C VGM
Zacks News
National Vision (EYE) Q1 Earnings Top Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 22.22% and 4.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 37.50% and 11.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm (VAPO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vapotherm (VAPO) delivered earnings and revenue surprises of -38.10% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of -8.33% and 4.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
New Strong Sell Stocks for September 22nd
by Zacks Equity Research
MANU, GRFS, IMCC, and INTZ have been added to the Zacks Rank #5 (Strong Sell) List on September 22, 2021